Skip to main content
Premium Trial:

Request an Annual Quote

SeekIn Receives CE-IVD Mark for Leukemia Cancer Mutation Detection Kit

NEW YORK – Chinese cancer diagnostics firm SeekIn said Monday that it has received the CE mark for its PanCanSeek Cancer Mutation Detection Kit and now intends to market the test in the European Union and other regions that recognize the designation.

PanCanSeek uses high-depth whole-genome sequencing and is intended to support molecular typing, prognosis stratification, treatment guidance, and drug efficacy prediction for patients with hematologic cancers.

The test requires a 2 ml bone marrow sample and utilizes 50X sequencing to detect a variety of DNA alterations including single nucleotide variants, small insertions and deletions, copy number alteration, and structural variants.

Based in Shenzhen, China, SeekIn has CE-marked several other assays this year, including tests for cancer recurrence and treatment monitoring, molecular karyotyping, and multi-cancer early detection.

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.